Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images)

No­var­tis' first at­tempt to repli­cate a stun­ning can­cer re­sult falls flat

A decade ago, No­var­tis launched a 10,000-per­son tri­al to try to turn a rare dis­ease drug in­to the next heart dis­ease block­buster. In 2017, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.